Corundum Systems Biology Inc., a group company of Corundum Innovation Co., Ltd., participated in the Series A financing round that successfully raised USD23 million for Concerto Biosciences, a US biotechnology company making discoveries in microbial combinations to treat disease. Concerto will use the funds to advance product development based on designing microbial communities that restore deficient microbiomes. It will also expand its pipeline for products in medicine and agriculture. As an initial step, it will allocate funds for clinical studies for “Ensemble No. 2,” Concerto’s first microbial product, which aims to correct the microbial deficiency underlying atopic dermatitis.
For more details:
CSB Press Release:
https://www.csb.co.jp/archives/62881
Concerto Press Release:
About Corundum Innovation
Corundum Innovation Co., Ltd., and Corundum Ventures Ltd. (Hereafter Corundum) provide venture capital (VC) investment and consulting services to investors for both financial and strategic returns. Corundum provides flexible services to COIF’s investors for new business development in various phases with our expertise in science, technology, business development, corporate management, finance and consulting, as well as our strong network with top Israeli VC and the valuable information we can access through fund activities. Corundum’s support includes information gathering, negotiation for partnership, direct investment, market development, HR development, and fund formation.
Contact
Corundum Innovation Co., Ltd.
https://corundum.bz/en/contact/